# Maxcyte, Inc.: overview MXCT · Nasdaq · CIK 1287098 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mxct.md) · [Financials](/companies/mxct/financials.md) · [Filings](/companies/mxct/filings.md) · [Insiders](/companies/mxct/insiders.md) Latest reported revenue: [$4.9m](/filings/0001104659-26-095971.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-095971). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [5.6](/filings/0001104659-25-111396.md) | [6.1 d](/filings/0001104659-26-034557.md) | [5.7](/filings/0001104659-26-060290.md) | [5.8](/filings/0001104659-26-095971.md) | [4.6](/filings/0001104659-25-111396.md) | [4.8 d](/filings/0001104659-26-034557.md) | [4.5](/filings/0001104659-26-060290.md) | [4.9](/filings/0001104659-26-095971.md) | | Gross margin | % | [111.1%](/filings/0001104659-25-111396.md) | [105.9% d](/filings/0001104659-26-034557.md) | [154.8%](/filings/0001104659-26-060290.md) | [120.0%](/filings/0001104659-26-095971.md) | [113.7%](/filings/0001104659-25-111396.md) | [118.9% d](/filings/0001104659-26-034557.md) | [179.6%](/filings/0001104659-26-060290.md) | [113.4%](/filings/0001104659-26-095971.md) | | Operating margin | % | [(250.4%)](/filings/0001104659-25-111396.md) | [(213.1%) d](/filings/0001104659-26-034557.md) | [(214.1%)](/filings/0001104659-26-060290.md) | [(244.3%)](/filings/0001104659-26-095971.md) | [(307.4%)](/filings/0001104659-25-111396.md) | [(234.5%) d](/filings/0001104659-26-034557.md) | [(137.4%)](/filings/0001104659-26-060290.md) | [(207.3%)](/filings/0001104659-26-095971.md) | | Net margin | % | [(205.9%)](/filings/0001104659-25-111396.md) | [(175.0%) d](/filings/0001104659-26-034557.md) | [(178.7%)](/filings/0001104659-26-095971.md) | [(212.2%)](/filings/0001104659-26-095971.md) | [(269.7%)](/filings/0001104659-25-111396.md) | [(200.5%) d](/filings/0001104659-26-034557.md) | [(105.5%)](/filings/0001104659-26-095971.md) | [(179.8%)](/filings/0001104659-26-095971.md) | | Diluted EPS | $ per share | [(0.11)](/filings/0001104659-25-111396.md) | not reported | [(0.10)](/filings/0001104659-26-060290.md) | [(0.12)](/filings/0001104659-26-095971.md) | [(0.12)](/filings/0001104659-25-111396.md) | not reported | [(0.04)](/filings/0001104659-26-060290.md) | [(0.08)](/filings/0001104659-26-095971.md) | | Free cash flow | $m | [(4.8) d](/filings/0001104659-25-111396.md) | [(8.0) d](/filings/0001104659-26-034557.md) | [(15.1)](/filings/0001104659-26-060290.md) | [(10.4) d](/filings/0001104659-26-095971.md) | [(7.8) d](/filings/0001104659-25-111396.md) | [(2.9) d](/filings/0001104659-26-034557.md) | [(8.2)](/filings/0001104659-26-060290.md) | [(4.7) d](/filings/0001104659-26-095971.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [21.6](/filings/0001558370-23-003911.md) | [28.7](/filings/0001558370-24-003001.md) | [19.5](/filings/0001558370-25-002721.md) | [22.2](/filings/0001104659-26-034557.md) | [21.0](/filings/0001104659-26-034557.md) | | Gross margin | % | [140.2%](/filings/0001558370-23-003911.md) | [136.2%](/filings/0001558370-24-003001.md) | [187.4%](/filings/0001558370-25-002721.md) | [141.9%](/filings/0001104659-26-034557.md) | [127.9%](/filings/0001104659-26-034557.md) | | Operating margin | % | [(84.3%)](/filings/0001558370-23-003911.md) | [(95.2%)](/filings/0001558370-24-003001.md) | [(247.7%)](/filings/0001558370-25-002721.md) | [(230.5%)](/filings/0001104659-26-034557.md) | [(247.6%)](/filings/0001104659-26-034557.md) | | Net margin | % | [(88.5%)](/filings/0001558370-23-003911.md) | [(82.0%)](/filings/0001558370-24-003001.md) | [(194.5%)](/filings/0001558370-25-002721.md) | [(184.8%)](/filings/0001104659-26-034557.md) | [(213.0%)](/filings/0001104659-26-034557.md) | | Diluted EPS | $ per share | [(0.21)](/filings/0001558370-23-003911.md) | [(0.23)](/filings/0001558370-24-003001.md) | [(0.37)](/filings/0001558370-25-002721.md) | [(0.39)](/filings/0001104659-26-034557.md) | [(0.42)](/filings/0001104659-26-034557.md) | | Free cash flow | $m | [(14.5)](/filings/0001558370-23-003911.md) | [(33.3)](/filings/0001558370-24-003001.md) | [(25.4)](/filings/0001558370-25-002721.md) | [(29.3)](/filings/0001104659-26-034557.md) | [(36.2)](/filings/0001104659-26-034557.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mxct/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Capricorn Fund Managers Ltd](/funds/1901361.md) | 2026-06-30 | $10.1m | 8,200,000 | | Unchanged | | [Vitruvian Partners LLP](/funds/1692590.md) | 2026-06-30 | $6.2m | 5,043,356 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.0m | 4,031,284 | | Added +49,468 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $4.5m | 3,694,049 | | Added +5,918 | | [Mudita Advisors LLP](/funds/1907809.md) | 2026-06-30 | $4.1m | 3,370,689 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.8m | 3,060,960 | | Reduced −5,737,513 | | [Brooklands Fund Management Ltd](/funds/2036388.md) | 2026-06-30 | $3.7m | 2,848,083 | | Added +658,063 | | [BNP PARIBAS ASSET MANAGEMENT Holding S.A.](/funds/1520354.md) | 2026-06-30 | $3.4m | 2,773,554 | | Unchanged | | [CADIAN CAPITAL MANAGEMENT, LP](/funds/1423686.md) | 2026-06-30 | $2.7m | 2,201,166 | | Added +478,224 | | [Peapod Lane Capital LLC](/funds/2050979.md) | 2026-06-30 | $2.6m | 2,125,752 | | Added +793,559 | ## Recent filings [All 324 filings](/companies/mxct/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-15 | 13:00 ET | [SCHEDULE 13D](/filings/0001544204-26-000009.md) | Ownership report, active investor | 0001544204-26-000009 | | 2026-10-14 | 12:10 ET | [8-K](/filings/0001104659-26-115745.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-115745 | | 2026-08-13 | 20:32 ET | [10-Q](/filings/0001104659-26-095971.md) | Quarterly report, period 2026-06-30 | 0001104659-26-095971 | | 2026-08-12 | 20:14 ET | [8-K](/filings/0001104659-26-094886.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-094886 | | 2026-08-04 | 12:42 ET | [SCHEDULE 13D](/filings/0001486180-26-000003.md) | Ownership report, active investor | 0001486180-26-000003 | | 2026-06-17 | 20:59 ET | [8-K](/filings/0001104659-26-075211.md) | 5.07 Shareholder vote results | 0001104659-26-075211 | | 2026-06-16 | 20:21 ET | [8-K](/filings/0001104659-26-074594.md) | 3.01 Delisting notice | 0001104659-26-074594 | | 2026-05-14 | 13:44 ET | [SCHEDULE 13D](/filings/0001486180-26-000002.md) | Ownership report, active investor | 0001486180-26-000002 | | 2026-05-13 | 20:31 ET | [10-Q](/filings/0001104659-26-060290.md) | Quarterly report, period 2026-03-31 | 0001104659-26-060290 | | 2026-05-12 | 20:12 ET | [8-K](/filings/0001104659-26-059399.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-059399 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-034557.md), filed Mar 25, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1287098 - Tickers: MXCT - Exchange: Nasdaq - SIC code: 8731 Services-Commercial Physical & Biological Research - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.